Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries Identifier:
First received: January 31, 2013
Last updated: May 8, 2014
Last verified: May 2014

The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).

Condition Intervention Phase
Allergic Rhinitis
Drug: BDP Nasal Aerosol
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Average AM and PM daily reflective Total Nasal Sympton Score (rTNSS) over the first 6 weeks of treatment for subjects 6 - 11 years of age [ Time Frame: Baseline to Week 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Average AM and PM subject-reported instantaneous Total Nasal Symptom Score (iTNSS) over the first 6 weeks of treatment for subjects 6-11 years of age [ Time Frame: Baseline to Week 6 ] [ Designated as safety issue: No ]

Enrollment: 547
Study Start Date: January 2013
Study Completion Date: November 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BDP Nasal Aerosol
BDP nasal aerosol: 80 mcg dose once daily. Participants/patients will administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
Drug: BDP Nasal Aerosol
Other Name: Beclomethasone dipropionate
Placebo Comparator: Placebo Nasal Aerosol
Placebo nasal aerosol: Participants/patients will administer placebo (no medication) (one spray per nostril) during the 12-week Treatment Period.
Drug: Placebo


Ages Eligible for Study:   4 Years to 11 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects 4 to 11 years of age, inclusive, as of the Screening Visit (SV).
  • A documented history of PAR to a relevant perennial allergen for a minimum of 12 months (6 months for subjects 4 to 5 years of age) immediately preceding the study Screening Visit (SV).
  • A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test.
  • Other criteria apply.

Exclusion Criteria:

  • History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit [SV]).
  • History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis or influenza) within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-In Period.
  • Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable.
  • Have any of the following conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial.
  • Other criteria apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01783548

  Show 63 Study Locations
Sponsors and Collaborators
Teva Pharmaceutical Industries
  More Information

No publications provided

Responsible Party: Teva Pharmaceutical Industries Identifier: NCT01783548     History of Changes
Other Study ID Numbers: BDP-AR-306
Study First Received: January 31, 2013
Last Updated: May 8, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Teva Pharmaceutical Industries:
allergic rhinitis
pediatric subjects
BDP nasal aerosol

Additional relevant MeSH terms:
Rhinitis, Allergic, Perennial
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on October 09, 2015